Amiloride: A Potential New Treatment for Anxiety

Research Overview

Recent studies indicate that amiloride, a medication primarily used to treat high blood pressure, may serve as an effective treatment for anxiety when delivered as a nasal spray. This research, conducted by the Centre for Addiction and Mental Health (CAMH) in Canada, has been published in the Journal of Psychopharmacology.

Impact of Early Life Experiences on Mental Health

Early life experiences significantly influence both mental and physical health. Adverse events during formative years can alter biological mechanisms, leading to increased susceptibility to anxiety disorders as individuals grow older. Traditional treatments for anxiety typically involve antidepressants and psychotherapy, but this new evidence suggests an alternative approach utilizing amiloride.

Genetic Changes and Anxiety

The study focuses on genetic alterations in acid-sensing ion channels (ASIC) within the brain, which can result from negative early-life experiences. Such experiences affect the functionality of ASIC genes, impacting physical symptoms associated with anxiety. For instance, elevated carbon dioxide levels can trigger hyperventilation, exacerbating feelings of anxiety.

Mechanism of Amiloride in Anxiety Treatment

Amiloride’s potential role in treating anxiety is linked to its function as an ASIC inhibitor. By regulating the body’s response to carbon dioxide levels, amiloride may help mitigate anxiety symptoms. In this study, amiloride was administered as an inhalation to ensure it reached the brain effectively, as oral administration did not yield the desired therapeutic effects.

Study Methodology

The research involved two groups of mice. One group underwent a process known as repeated cross-fostering (RCF), where newborn mice were separated from their biological mothers and raised by other lactating females. This method simulates the effects of negative early-life experiences, including separation anxiety. The control group of mice remained with their biological mothers.

Findings on Anxiety Reduction

The researchers hypothesized that a single inhaled dose of amiloride would diminish hyperventilation responses in RCF mice exposed to carbon dioxide. The results confirmed this hypothesis, showing that treated RCF mice exhibited reduced physical signs of anxiety, with sensitivity to carbon dioxide returning to levels comparable to those of the control group.

Future Directions

These preclinical findings highlight amiloride’s potential as a novel treatment for anxiety. The next phase of research will involve a pilot clinical trial to assess whether nasally inhaled amiloride can effectively alleviate anxiety symptoms in humans.

References

Battaglia, M., Rossignol, O., Bachand, K., D’Amato, F. R., & Koninck, Y. D. (2018). Amiloride modulation of carbon dioxide hypersensitivity and thermal nociceptive hypersensitivity induced by interference with early maternal environment. Journal of Psychopharmacology, 026988111878487. doi:10.1177/0269881118784872

O’Malley, S. (2018, September 11). Inhaled version of blood pressure drug shows promise in treating anxiety, pain. Retrieved from https://www.eurekalert.org/pub_releases/2018-09/cfaa-ivo091118.php